Alder BioPharmaceuticals (NASDAQ:ALDR) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 2 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. Alder BioPharmaceuticals (NASDAQ:ALDR) stock ended Thursday session in the red zone in a volatile trading. The stock closed down 0.57 points or 3.23% at $17.08 with 866,599 shares getting traded. Post opening the session at $17.51, the shares hit an intraday low of $15.8201 and an intraday high of $17.76 and the price was in this range throughout the day. The company has a market cap of $747 million and the number of outstanding shares have been calculated to be 43,757,235 shares. The 52-week high of Alder BioPharmaceuticals (NASDAQ:ALDR) is $54.9 and the 52-week low is $15.8201.
Alder BioPharmaceuticals (NASDAQ:ALDR): 2 Analyst have given the stock of Alder BioPharmaceuticals (NASDAQ:ALDR) a near short term price target of $49.5. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $12.02. The higher price target estimate is at $58 while the lower price estimates are fixed at $41.
The stock has recorded a 20-day Moving Average of 13.7% and the 50-Day Moving Average is 27.35%. Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange,The officer (Chief Business Officer) of Alder Biopharmaceuticals Inc, Litton Mark James sold 25,000 shares at $31.52 on January 4, 2016. The Insider selling transaction had a total value worth of $788,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.